From Nasdaq: 2025-03-27 18:36:00

Novo Nordisk’s stock took a hit after a Morgan Stanley analyst lowered the price target for the company’s shares. Concerns were raised about the lower subscription numbers for its obesity medication, Wegovy, compared to rival Eli Lilly’s Zepbound. The competition is tough in the obesity market, with Novo Nordisk facing challenges from other companies developing similar products. Analysts anticipate a possible cut in full-year guidance for 2025, putting pressure on the company to maintain its position in the segment.

Missed out on investing in successful stocks? Analysts are offering a “Double Down” stock recommendation for companies with potential growth. Past returns for companies like Nvidia, Apple, and Netflix have been significant, making it a lucrative opportunity for investors to consider. Don’t miss this chance to invest in companies with high growth potential before it’s too late.



Read more at Nasdaq: Why Novo Nordisk Stock Dipped on Thursday